Shield Therapeutics plc
("Shield" or the "Company" or the
"Group")
Notice of
Results
Investor
Presentation
London, UK, 16 April 2024: Shield
Therapeutics plc (LSE: STX), a commercial-stage
pharmaceutical company that delivers Accrufer®/Feraccru® (ferric
maltol), an innovative and differentiated specialty pharmaceutical
product, to address a significant unmet need for patients suffering
from iron deficiency (with or without anemia), will announce its final results for the year ended 31 December
2023 on Tuesday 30 April 2024.
Investor presentation
CEO, Greg Madison, and CFO, Santosh
Shanbhag, will be hosting a live online presentation relating to
the final results via the Investor Meet Company platform
at 14.30 (BST) on Tuesday 30 April 2024.
The presentation is open to all
existing and potential investors. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for
free and add to meet Shield Therapeutics plc via:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
Investors who already follow Shield Therapeutics
plc on the Investor Meet Company platform will automatically be
invited.
For further
information please contact:
|
Shield Therapeutics
plc
|
www.shieldtherapeutics.com
|
|
Greg Madison, CEO
|
+44 (0) 191 511 8500
|
|
Santosh Shanbhag, CFO
|
|
|
Nominated Adviser
and Joint Broker
|
|
|
Peel Hunt
LLP
|
|
|
James Steel/Patrick
Birkholm
|
+44 (0)20 7418 8900
|
|
Joint
Broker
Cavendish Ltd
Geoff Nash/George Dollemore/Nigel Birks/ Harriet
Ward
|
+44 (0)20 7220 0500
|
|
|
|
|
Financial PR & IR Advisor
|
|
|
Walbrook PR
|
|
|
Paul McManus/Charlotte
Edgar/
Alice Woodings
|
+44 (0)20
7933 8780
shield@walbrookpr.com
|
|
|
|
|
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly
|
+1 617 429 3548 or
jmullaly@lifesciadvisors.com
|
About
Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel,
stable, non-salt based oral therapy for adults with iron
deficiency, with or without anemia. Accrufer®/Feraccru® has a novel
mechanism of action compared to other oral iron therapies and has
been shown to be an efficacious and well-tolerated therapy in a
range of clinical trials. More information about
Accrufer®/Feraccru®, including the product label, can be found at:
www.accrufer.com and www.feraccru.com
About Shield
Therapeutics plc
Shield is a commercial stage pharmaceutical company
focused on the commercialisation of Accrufer®/Feraccru® (ferric
maltol), an innovative oral iron therapy for iron deficiency
differentiated from other irons by its efficacy, broad label and
well-tolerated formulation. The Group has launched
Accrufer® in the US with an exclusive, multi-year collaboration
agreement with Viatris, Inc. Feraccru® is commercialised in the UK
and European Union by Norgine B.V., that also have the marketing
rights in Australia and New Zealand. Shield also has an
exclusive license agreement with Beijing Aosaikang Pharmaceutical
Co., Ltd., for the development and commercialisation of Accrufer® /
Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma
Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals
Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the
mid-2030s
Accrufer®/Feraccru® are registered trademarks of the
Shield Group
